呼吸窘迫综合征最新病历资料.ppt

ARDS -- role of ketoconazole Randomized, double-blind, placebo-controlled trial from March 1996 to January 1997 24 hospitals associated with 10 network centers in the United States PATIENTS A total of 234 pts with ALI or ARDS INTERVENTION: ketoconazole, 400 mg/d (n = 117) placebo (n = 117) initiated within 36 hours of fulfilling study entry criteria and given enterally for up to 21 days Ketoconazole – an antifungal with immunomodulatory effect CONCLUSION: In these patients with ALI or ARDS, ketoconazole was safe and bioavailable but did not reduce mortality or duration of mechanical ventilatio